Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425029 | 0.83 | LIPG (0.40) | LPLLIPGFFAR1F11AAK1 | |
| SCHEMBL552417 | 0.82 | LPL (0.34) | LPLLIPGFFAR1F11AAK1 | |
| SCHEMBL2428673 | 0.81 | LIPG (0.45) | LPLLIPGFFAR1F11AAK1 | |
| SCHEMBL2026626 | 0.80 | F11 (0.42) | LPLLIPGFFAR1F11GSK3A | |
| SCHEMBL17048093 | 0.78 | LIPG (0.58) | LPLLIPGFFAR1F11AAK1 | |
| SCHEMBL12373176 | 0.78 | LPL (0.44) | LPLLIPGFFAR1F11 | |
| SCHEMBL23031440 | 0.77 | LIPG (0.62) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL551592 | 0.77 | CHRNB2 (0.41) | LPLLIPGFFAR1F11GSK3A | |
| SCHEMBL3645868 | 0.77 | LIPG (0.38) | LPLLIPGFFAR1F11GSK3A | |
| SCHEMBL17847042 | 0.77 | F11 (0.40) | LPLLIPGFFAR1F11AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4514788-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | US | disclosed |
| EP-3233802-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097013-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | PTGER1, PTGES, PTGES3 | LPL 2809/4885LIPG 1050/4885FFAR1 873/4885 |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | PTGER1, PTGES, PTGES3 | LPL 2809/4885LIPG 1050/4885FFAR1 873/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | LPL 2320/4885LIPG 1956/4885FFAR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.